Table 1.

Primary and secondary resistance mutations in the protease gene based on differences in the nucleotide sequences obtained from plasma and PBMC

PatientTreatmentaSampleMutation(s) associated with resistance to protease inhibitorsb
PrimarySecondary
M46G48V82L90L10K20L24L33I47I54L63A71V77I84N88I93
P1ddC + d4t + IDVPBMCL/MIPVL
PlasmaIPVVL
P2ZDV + 3TC + SQVPBMC
PlasmaA/I
P33TC + d4t + SQVPBMCK/RP
PlasmaK/RPT
P4ZDV + 3TC + RTVPBMCIPL
PlasmaAIPI/VL
P5ZDV + 3TC + NELFIPBMCPVIL
PlasmaIPVIN/DL
P63TC + d4t + IDVPBMCPA/VL
PlasmaIL/RPVL
P7ddI + d4t + IDVPBMCK/MV/AI
PlasmaIL/MII/LVI
P8ddI + 3TC + SQV + RTVPBMCP
PlasmaIV/GAPV
P9ddI + d4t + IDVPBMCL
PlasmaLAIIL
P10d4t + 3TC + IDVPBMCPV/AI
PlasmaAIVPVI
P11ZDV + 3TC + RTVPBMCM/IA/VM/LI/VPV/AIL
PlasmaIAMI/LVPVIL
P12ZDV + 3TC + IDVPBMCI/MI/LI/TPT/AS/G
PlasmaII/LIPTS
  • a Abbreviations: ddC, dideoxycytosine; d4t, stavudine; IDV, indinavir; ZDV, zidovudine; 3TC, lamivudine; SQV, saquinavir; NELFI, nelfinavir; ddI, dideoxyinosine; RTV, ritonavir.

  • b Mutations are indicated as amino acid changes. When mixed genomes are detected, the amino acids found are indicated and separated with a slash (e.g., L/M for patient P1 at position L90).